On 2 February, at the Late-Breaking Science Session at the International Stroke Conference, the results of the TREVO study (Thrombectomy revascularization of large vessel occlusions in acute ischaemic stroke) were presented. TREVO is one of the first prospective, multicentre clinical studies of clot-removing stent retriever technology. Sixty patients were enrolled by seven leading stroke centres in Europe.
The TREVO study was designed to assess the ability of the Trevo system (Stryker) to remove the blood clots that cause strokes and to restore blood flow to the brain. Revascularisation was measured by an independent core lab.
The results were presented at the International Stroke Conference in New Orleans, USA, by Nils Wahlgren, co-principal investigator of the study and professor of Neurology at Karolinska University Hospital, Solna, Sweden. The results demonstrated high revascularisation rates of 91.7%. Forty six per cent of patients achieved a good outcome in just seven days, and at 90 days, the good outcomes rate increased to 55%. These patients with good outcomes were functionally independent (modified Rankin score of two or less). A low symptomatic intracranial haemorrhage rate of 5% was also reported.
“The TREVO study represents an important step forward in the evidence supporting the treatment of patients with moderate and severe strokes with mechanical thrombectomy devices, such as the Trevo system. The rigorous conduct of this prospective multicentre trial provides more confidence not only in patient selection, but in the successful procedural and clinical outcomes that can be achieved for these patients,” Wahlgren said.
